ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalization and Emergency Department Visits Associated With Respiratory Syncytial Virus in Older Adults: A Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Pooled it
- Bivalent RSVpreF Effectiveness Against Respiratory Syncytial Virus (RSV)-Related Respiratory Disease Hospitalization and Emergency Department Visits Across Three RSV Seasons.Infectious diseases and therapy · 2026Article
- The Impact of Respiratory Syncytial Virus Undertesting on Estimates of Disease Burden and Vaccine Effectiveness in a Large Integrated Healthcare System.Open forum infectious diseases · 2026Article
- Bivalent RSVpreF effectiveness against RSV-associated hospital or emergency department care over two seasons: a retrospective test-negative case control study.Lancet regional health. Americas · 2026Article
- Evaluating Analytic Approaches to Determining Respiratory Syncytial Virus Seasonality-United States, 2014-2024.Influenza and other respiratory viruses · 2026Article
- Socioeconomic value of adult respiratory vaccination in the United States: a benefit-cost analysis.Health affairs scholar · 2026Article
- Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis.The Lancet regional health. Europe · 2026Article
- How do Recent Population-Level RSVpreF Vaccine-Impact Results from the United Kingdom Relate to Previously Reported Vaccine Effectiveness Results?Infectious diseases and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is an important cause of severe respiratory illness among older adults. Previously, we showed that the RSVpreF vaccine (Abrysvo; Pfizer) prevents RSV-related lower respiratory tract disease-related emergency department (ED) visits/hospitalizations in older adults. Here, we evaluate its effectiveness against additional acute respiratory illness (ARI) end points, including severe disease, among high-risk persons.
methodsThis was a retrospective test-negative case-control study of adults aged ≥60 years at Kaiser Permanente Southern California with ARI ED visits/hospitalizations, defined by International Classification of Diseases, Tenth Revision discharge code, from 24 November 2023 to 9 April 2024. Case patients tested positive for RSV. Controls in the primary analysis tested negative for RSV, human metapneumovirus, influenza, and severe acute respiratory syndrome coronavirus 2 and positive for a non-vaccine-preventable pathogen. The exposure was RSVpreF receipt ≥21 days before ARI diagnosis. Vaccine effectiveness (VE) was calculated from adjusted odds ratios via multivariable logistic regression.
resultsOverall, 8965 ARI ED visits/hospitalizations with RSV testing were included; 7.8% of patients were RSV positive, among whom 0.3% had received RSVpreF, compared with 3.6% of controls. The adjusted VE was 92% (95% confidence interval, 64%-98%). We estimated similar VE among patients with risk conditions (92% [95% confidence interval: 65%-98%]), the oldest subgroup (age ≥75 years; 95% [60%-99%]), those with critical outcomes (intensive care unit admission, mechanical ventilation, respiratory failure, vasopressor use, or death; 90% [16%-99%]), and those with severe disease (defined as ED visit or hospitalization requiring oxygen; 92% [35%-99%]).
conclusionsAmong older adults, RSVpreF demonstrated high VE against RSV-related ARI hospitalization or ED visits, including among high-risk subgroups, and against severe outcomes. RSV vaccination programs can protect groups at the highest risk of severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.